References
- Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(9):1027–1041.
- Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
- Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204.
- Wu PA, Kim YH, Lavori PW, et al. A Meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant. 2009;15(8):982–990.
- Lechowicz MJ, Lazarus HM, Carreras J, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49(11):1360–1365.
- Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492–4499.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphoma Version 2.2022. National Comprehensive Cancer Network. 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf
- Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41(7):597–604.
- Polansky M, Talpur R, Daulat S, et al. Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients with Sézary syndrome. Clin Lymphoma Myeloma Leuk. 2015;15(5):e83–e93.
- Iqbal M, Reljic T, Ayala E, et al. Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2020;26(1):76–82.
- Delioukina M, Zain J, Palmer JM, et al. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant. 2012;47(1):65–72.
- Mori T, Shiratori S, Suzumiya J, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome. Hematol Oncol. 2020;38(3):266–271.
- Isufi I, Seropian S, Gowda L, et al. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leuk Lymphoma. 2020;61(12):2955–2961.
- Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
- Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–288.
- Kanakry JA, Kasamon YL, Gocke CD, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013;19(4):602–606.
- Ghosh N, Karmali R, Rocha V, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016;34(26):3141–3149.
- Schoch LK, Cooke KR, Wagner-Johnston ND, et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv. 2018;2(17):2226–2229.
- Sahebi F, Garderet L, Kanate AS, et al. Outcomes of haploidentical transplantation in patients with relapsed multiple myeloma: an EBMT/CIBMTR report. Biol Blood Marrow Transplant. 2019;25(2):335–342.
- Fatobene G, Rocha V, St Martin A, et al. Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR. J Clin Oncol. 2020;38(14):1518–1526.
- Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–3671.
- Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295–304.
- Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956.
- Dimitriou F, Schanz U, Nair G, et al. Long-term disease control after allogeneic hematopoietic stem cell transplantation in primary cutaneous T-cell lymphoma; results from a single institution analysis. Front Med. 2020;7:290.
- Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490–2495.
- Méchineaud M, Mercier M, Le Corre Y, et al. Cutaneous and systemic T-cell lymphoma treated with haploidentical bone marrow transplantation. Ann Dermatol Venereol. 2018;145(6–7):439–444.
- Baron MK, Osborn JD, Tao R, et al. Haploidentical hematopoietic cell transplantation for mycosis fungoides/Sezary syndrome. Leuk Lymphoma. 2020;61(1):231–233.
- Kanda-Kato M, Yoshioka S, Ishikawa T. Haploidentical hematopoietic cell transplantation using posttransplant cyclophosphamide for Sézary syndrome. Case Rep Oncol. 2020;13(2):1053–1058.
- Paul S, Zahurak M, Luznik L, et al. Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic Hodgkin lymphoma: a retrospective cohort study. Biol Blood Marrow Transplant. 2020;26(9):1679–1688.
- Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017;129(10):1380–1388.
- Saberian C, Abdel-Wahab N, Abudayyeh A, et al. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2021;9(2):e001818.
- Oran B, Garcia-Manero G, Saliba RM, et al. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020;126(10):2193–2205.
- Kallies A, Zehn D, Utzschneider DT. Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol. 2020;20(2):128–136.